NCT02182219View on ClinicalTrials.gov

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 1, 2005

Primary Completion Date

April 1, 2007

Conditions
Prostatic Neoplasms
Interventions
DRUG

BIBF 1120

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02182219 - Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter